OrbusNeich Medical Group Holdings (HKG:6929) Full Year 2024 Results
Key Financial Results
- Revenue: US$164.1m (up 6.6% from FY 2023).
- Net income: US$39.7m (down 12% from FY 2023).
- Profit margin: 24% (down from 29% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: US$0.048 (down from US$0.054 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
OrbusNeich Medical Group Holdings Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 2.9%.
Looking ahead, revenue is forecast to grow 8.5% p.a. on average during the next 2 years, compared to a 27% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are up 1.4% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of OrbusNeich Medical Group Holdings' balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.